Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Callahan MK, Wolchok JD.

J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10. Review.

2.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

3.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
4.

Checkpoint blocking antibodies in cancer immunotherapy.

Kyi C, Postow MA.

FEBS Lett. 2014 Jan 21;588(2):368-76. doi: 10.1016/j.febslet.2013.10.015. Epub 2013 Oct 23. Review.

5.

Immune Checkpoint Blockade in Cancer Therapy.

Postow MA, Callahan MK, Wolchok JD.

J Clin Oncol. 2015 Jun 10;33(17):1974-82. doi: 10.1200/JCO.2014.59.4358. Epub 2015 Jan 20. Review.

6.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

7.

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

Tanvetyanon T, Gray JE, Antonia SJ.

Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18. Review.

PMID:
28064556
8.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Pennock GK, Chow LQ.

Oncologist. 2015 Jul;20(7):812-22. doi: 10.1634/theoncologist.2014-0422. Epub 2015 Jun 11. Review.

9.

Targeting T Cell Co-receptors for Cancer Therapy.

Callahan MK, Postow MA, Wolchok JD.

Immunity. 2016 May 17;44(5):1069-78. doi: 10.1016/j.immuni.2016.04.023. Review.

10.

Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.

Azoury SC, Straughan DM, Shukla V.

Curr Cancer Drug Targets. 2015;15(6):452-62. Review.

PMID:
26282545
11.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
12.

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.

Swanson MS, Sinha UK.

Oral Oncol. 2015 Jan;51(1):12-5. doi: 10.1016/j.oraloncology.2014.10.010. Epub 2014 Oct 28. Review.

PMID:
25459157
13.

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD.

Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Review.

PMID:
24880949
14.

Mechanistic and pharmacologic insights on immune checkpoint inhibitors.

Sweis RF, Luke JJ.

Pharmacol Res. 2017 Jun;120:1-9. doi: 10.1016/j.phrs.2017.03.012. Epub 2017 Mar 18. Review.

PMID:
28323141
15.

Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.

Chow LQ.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e280. Review.

16.

Cancer immunotherapy highlights from the 2014 ASCO Meeting.

Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N.

Cancer Immunol Res. 2014 Aug;2(8):714-9. doi: 10.1158/2326-6066.CIR-14-0119.

17.

Therapeutic use of anti-CTLA-4 antibodies.

Blank CU, Enk A.

Int Immunol. 2015 Jan;27(1):3-10. doi: 10.1093/intimm/dxu076. Epub 2014 Jul 18. Review.

PMID:
25038057
18.

Second- and third-generation drugs for immuno-oncology treatment-The more the better?

Dempke WCM, Fenchel K, Uciechowski P, Dale SP.

Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10. Review.

PMID:
28335888
19.

The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.

van Dam LS, de Zwart VM, Meyer-Wentrup FA.

Pediatr Blood Cancer. 2015 Feb;62(2):190-197. doi: 10.1002/pbc.25284. Epub 2014 Oct 18. Review.

PMID:
25327979
20.

The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Horn L, Reck M, Spigel DR.

Oncologist. 2016 Aug;21(8):910-21. doi: 10.1634/theoncologist.2015-0523. Epub 2016 Jun 27. Review.

Supplemental Content

Support Center